3SBio Inc stock (HK1530013386): Chinese biotech eyes hepatitis B expansion

3SBio Inc, a leading Chinese biopharma player, continues to advance its pipeline amid China's booming biotech sector, offering potential exposure for US investors tracking Asian healthcare growth.

3SBio Inc maintains a strong position in China's biopharmaceutical market with recent developments in its hepatitis B and other therapeutic areas. The company, listed on the Hong Kong Stock Exchange, reported steady progress in its core franchises as of its latest updates. Investors monitoring Chinese biotech stocks note 3SBio's focus on innovative therapies amid regulatory tailwinds in China.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: 3SBio Inc
• Sector/industry: Biopharmaceuticals
• Headquarters/country: China
• Core markets: China, Asia
• Key revenue drivers: Oncology, nephrology, hepatitis therapies
• Home exchange/listing venue: Hong Kong Stock Exchange (1530.HK)
• Trading currency: HKD

3SBio Inc: core business model

3SBio Inc develops, manufactures and markets biopharmaceutical products primarily in China. The company specializes in recombinant proteins, monoclonal antibodies and small molecule drugs targeting oncology, nephrology, dermatology and other areas. Its flagship product EPIAO, a recombinant human erythropoietin, has been a mainstay since 2003, treating anemia in chronic kidney disease patients. 3SBio operates a fully integrated model from R&D to commercialization, with over 3,000 employees supporting its operations.

The business benefits from China's expanding healthcare access and aging population, driving demand for chronic disease treatments. 3SBio has built a network of over 10,000 hospitals for distribution, ensuring broad market penetration. This model positions it well for US investors seeking exposure to China's $150 billion biopharma market, as per Statista as of 2025.

Main revenue and product drivers for 3SBio Inc

Oncology remains a top revenue contributor, led by products like TPIAO (pegylated recombinant human interleukin-11) for chemotherapy-induced thrombocytopenia. Nephrology follows with EPIAO and pegylated versions generating consistent sales. In immunology and dermatology, 3SBio's SSJ (etanercept biosimilar) treats rheumatoid arthritis and psoriasis. Recent pipeline advancements include hepatitis B candidates, aligning with China's high prevalence of chronic HBV affecting over 70 million people.

For the fiscal year ended December 31, 2024, published March 2025, 3SBio reported revenue growth driven by volume expansion in core products, according to its IR filings as of March 2025. The company invests about 15% of revenue in R&D, supporting over 20 clinical-stage assets. This focus on high-prevalence diseases in China provides a defensive growth profile for investors.

Industry trends and competitive position

China's biopharma sector is projected to grow at 8-10% CAGR through 2030, fueled by policy reforms like the National Reimbursement Drug List expansions. 3SBio competes with global giants like Roche and local players like Innovent Biologics, but differentiates through its early-mover status in biosimilars. Its cost-efficient manufacturing gives pricing advantages in volume-driven markets.

Recent partnerships, such as deals mirroring GSK's hepatitis B collaborations in China, highlight sector momentum. 3SBio's HBV assets could tap similar distribution networks, enhancing commercialization prospects. For US investors, this offers indirect play on China's healthcare reforms impacting global supply chains.

Why 3SBio Inc matters for US investors

3SBio provides US investors with targeted exposure to China's biopharma boom without direct mainland listing risks. Traded as an ADR or via Hong Kong access, it benefits from US-China healthcare trade flows. The company's oncology and nephrology focus aligns with global megatrends, while its HKD listing offers currency diversification.

Conclusion

3SBio Inc stands as a established player in China's biopharma landscape, with robust product franchises and a promising pipeline in high-need areas like hepatitis B and oncology. While regulatory and competitive dynamics shape its path, the company's integrated model and market position support ongoing relevance. US investors may track its progress amid broader Asia healthcare trends.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.